65,437 trials
HIV Infections · Herpes Genitalis
Primary: Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis) — 95; 110 participants — p=<0.05
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 183; 169 days
Osteoarthritis
Primary: Gait Velocity — 107.5; 79.7 cm/s
CAD
Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants
Pancreatic Cancer
Primary: Number of Patients With Progression-free Survival — 10 participants
Peripheral Arterial Disease
Primary: Length of Exercise Duration on the Treadmill Constant Work Rate Exercise Test — 15.15; 21.40 minutes — p=0.033
Urinary Incontinence
Primary: 24 Month Cumulative Success Rate Computed From Kaplan Meier Time-to-event Analysis (Reported as Percent Success). — 38; 47 % success at 24 months — p=0.01
Healthy Volunteers
Primary: Overall Inter-Rater Reliability of Assessing Overall Eyelash Prominence Using the Japanese Global Eyelash Assessment Scale (GEA-J) at Day 1 — 0.891 Kendall's W
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
Pain
Primary: Change From Baseline in Mean Central Neuropathic Pain 11-Point Numerical Rating Scale Scores at the End of Treatment (up to 51 Days). — -0.74; -0.69 units on a scale…
Colorectal Neoplasms · Neoplasm Metastasis
Primary: Overall Survival (OS) — 12.06; 13.50 months — p=0.0032
Depression · Medication Administered in Error · Cognitive Impairment
Primary: Proportion of Subjects Cognitively Impaired in Emergency Medical Services (EMS) — 17 percentage of subjects
Idiopathic Restless Legs Syndrome
Primary: Severity of Restless Legs Syndrome (RLS) at Bedtime — -2.2; 5.2 units on a scale